Your essential biotech, medtech, and pharma recap — no noise, just what matters.

Revolution Medicines was "the talk of the town" at AACR this week, as STAT put it, and yesterday's data explained why. The combination of daraxonrasib plus standard chemotherapy (gemcitabine/nab-paclitaxel) delivered a 58% confirmed response rate in previously untreated metastatic pancreatic cancer. For context, gemcitabine/nab-paclitaxel alone historically produces response rates of approximately 23% in this setting. Daraxonrasib monotherapy hit 47%. The combination nearly doubled monotherapy and more than doubled historical chemo response rates. Median PFS and OS were not yet mature at the December 2025 data cutoff, which means patients are still alive and progressing slowly enough that the curves have not crossed the median threshold. That is itself a positive signal. Safety was manageable and consistent with the known profiles of each agent individually. These data directly support the design of the Phase 3 RASolute 303 trial that began dosing April 2. But the real surprise was RM-055. Revolution unveiled an entirely new class of compound: catalytic RAS(ON) inhibitors that do not just block RAS signaling but actively convert mutant RAS back to its inactive state. CEO Mark Goldsmith called it "a novel class." In preclinical models, RM-055 overcame resistance to existing RAS inhibitors, which is the key limitation of current targeted therapies. If RM-055 translates to the clinic, Revolution has a next-generation franchise waiting behind daraxonrasib. 👉 Read Full Analysis

Revolution Medicines Delivers 58% Response Rate in First-Line Pancreatic Cancer at AACR RVMD

What Happened: Revolution Medicines presented updated Phase 1/2 data from two trials of daraxonrasib in previously untreated metastatic pancreatic cancer at AACR 2026 on April 21.

Combination Data (daraxonrasib + GnP, Abstract LB407): From the RMC-GI-102 trial. 40 patients with previously untreated RAS-mutant metastatic PDAC received daraxonrasib 200mg once daily plus gemcitabine/nab-paclitaxel on a Day 1 and Day 15 schedule. Data cutoff December 1, 2025.

Monotherapy Data (Abstract LB337): From the RMC-6236-001 trial. 40 patients with previously untreated RAS-mutant metastatic PDAC received daraxonrasib 300mg daily.

Next-Gen Pipeline (RM-055, Abstract 6782): Revolution unveiled RM-055, a new class of mutant-targeted catalytic RAS(ON) inhibitors designed to convert mutant RAS from its active (ON) state back to its inactive (OFF) state, mimicking how normal RAS is regulated. In preclinical models, RM-055 drove deep, durable tumor regressions across KRAS G12 mutant pancreatic, NSCLC, and colorectal xenograft models, including tumors that had escaped prior RAS inhibitors. RM-055 preferentially suppressed mutant tumors versus normal tissues. Chief Scientific Officer Jan Smith said these catalytic inhibitors address "emergent resistance to RAS inhibitors," which has been a long-sought goal of the RAS research community.

Executive Impact: The 58% confirmed ORR in first-line combination therapy is the headline number. Historical gemcitabine/nab-paclitaxel response rates in this setting are approximately 23%. Adding daraxonrasib more than doubled that. The six-month PFS of 84% means the vast majority of first-line patients had not progressed at six months, which is remarkable in a disease where progression on chemo typically occurs within 5 to 6 months. These data validate the design of the RASolute 303 Phase 3 trial (first-line, mono + combo, all comers). Revolution also announced that full RASolute 302 data will be presented in an ASCO plenary session on May 31, and that daraxonrasib has received Breakthrough Therapy Designation from the FDA, further supporting an accelerated regulatory pathway.

👉 Read Full Analysis

The combination response rate needs to be understood against the historical baseline. In the MPACT trial that established gemcitabine/nab-paclitaxel as standard of care for first-line metastatic PDAC, the ORR was 23% with a median OS of 8.5 months. In the PRODIGE 4/ACCORD 11 trial that established FOLFIRINOX, the ORR was 31.6% with a median OS of 11.1 months.

Daraxonrasib plus GnP achieved 58% ORR in 40 patients. That is 2.5x the historical GnP response rate and nearly 2x the FOLFIRINOX rate. The six-month PFS of 84% is equally striking. In MPACT, six-month PFS was approximately 46%.

These are Phase 1/2 data in 40 patients with immature survival endpoints, so caution is warranted. Small sample sizes can produce inflated response rates. Selection bias in early-phase trials is real. But the consistency across monotherapy (47% ORR, 71% six-month PFS) and combination (58% ORR, 84% six-month PFS) data, combined with the Phase 3 RASolute 302 monotherapy OS data in 2L (13.2 months, HR 0.40), creates a coherent picture: daraxonrasib works in pancreatic cancer across lines of therapy and treatment approaches.

💊 RM-055: Why Resistance Matters

Every targeted therapy eventually faces resistance. Tumors adapt. They activate alternative signaling pathways, acquire secondary mutations, or alter expression levels. In the RAS inhibitor field, emergent resistance is already being observed with first-generation KRAS G12C inhibitors (sotorasib, adagrasib).

RM-055 addresses this problem through a fundamentally different mechanism. Instead of blocking RAS signaling (which RAS-addicted tumors can work around), RM-055 catalytically converts mutant RAS from the active ON state back to the inactive OFF state. It accelerates the GTP-to-GDP hydrolysis that mutant RAS proteins cannot perform on their own. In preclinical models, this mechanism drove tumor regressions even in tumors that had progressed on prior RAS inhibitors.

If this translates clinically, Revolution would have a sequence: daraxonrasib as the first-line RAS inhibitor, then RM-055 (or the combination) for patients who develop resistance. That is a franchise with a built-in next line of defense. CEO Goldsmith called it "a novel class." The RAS research community has been pursuing this catalytic approach for years. Revolution appears to be the first to demonstrate it works preclinically.

📊 AACR 2026: The Scoreboard

Revolution dominated, but other important data dropped this week at AACR:

AACR wraps today. The oncology conversation now shifts to ASCO (May 29 to June 2) where the full RASolute 302 dataset will get a plenary presentation on May 31.

🎯 Catalyst Calendar: April 2026 Forward

👉 Visit The Pro Hub

Is your company listed in the BioMed Nexus directory? 2,104 companies across 14 categories. Claim or upgrade your listing →

Sponsorship slots for 2026 are limited. See packages and pricing →